In the present study we showed a novel therapeutic strategy based on the use of AT101, an IgM specific for an epitope of GPC1 close to PDAC cell surface and able to selectively activate the CS and recruit effector cells in the tumor microenvironment, allowing to reduce tumor mass growth and improve survival in all treated mice. This evidence concerns the gene CD40LG and neoplasm.